PK Study of WD-1603 in Healthy Subjects

Parkinson Disease Clinical Trial

Official title: An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed Conditions

Status Recruiting

Clinical Trial Summary

An open label, balanced, randomised, four-treatment, four-period, four-sequence, single oral dose, crossover Pharmacokinetics study of WD-1603 carbidopa/levodopa extended-release tablets in normal, healthy, adult human subjects under fed conditions. A single oral dose of (either Treatment A or B or C or D) carbidopa/levodopa extended release tablets will be administered to each subject within 5 minutes after completion of standardized vegetarian breakfast under fed condition in each period as per randomization schedule.

Clinical Trial Description

This is an open label, balanced, randomised, four-treatment, four-period, four-sequence, single oral dose, crossover Pharmacokinetics study of WD-1603 carbidopa/levodopa extended-release tablets in normal, healthy, adult human subjects under fed conditions. A single oral dose of (either Treatment A or B or C or D) carbidopa/levodopa extended release tablets will be administered to each subject within 5 minutes after completion of standardized vegetarian breakfast under fed condition in each period as per randomization schedule. ;

Related Conditions & MeSH terms

• Parkinson Disease

• NCT number: NCT04591535
• Study type: Interventional
• Source: Hong Kong WD Pharmaceutical Co., Limited
• Contact: Xiaoxiong Wei, Doctor
• Phone: +86-21-6859-9718
• Email: xiaoxiong.wei@wdpharma.com
• Status: Recruiting
• Phase: Phase 1
• Start date: September 28, 2020
• Completion date: March 28, 2021